To overcome resistance of B16 Jak1-KO tumor cells to pmel ACT, we tested intratumoral delivery of BO-112, which has direct anti-tumor efficacy against B16 and augments anti-tumor efficacy of pmel ACT against B16. This evidence concerns the gene JAK1 and neoplasm.